IQV vs. ICLR, INCY, MEDP, CRL, NRC, OABI, MXCT, ABSI, LUNA, and NOTV
Should you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include ICON Public (ICLR), Incyte (INCY), Medpace (MEDP), Charles River Laboratories International (CRL), National Research (NRC), OmniAb (OABI), MaxCyte (MXCT), Absci (ABSI), Luna Innovations (LUNA), and Inotiv (NOTV). These companies are all part of the "commercial physical research" industry.
IQVIA (NYSE:IQV) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
89.6% of IQVIA shares are held by institutional investors. Comparatively, 95.6% of ICON Public shares are held by institutional investors. 1.6% of IQVIA shares are held by company insiders. Comparatively, 44.0% of ICON Public shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
IQVIA has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
In the previous week, IQVIA and IQVIA both had 9 articles in the media. IQVIA's average media sentiment score of 1.32 beat ICON Public's score of 0.62 indicating that IQVIA is being referred to more favorably in the media.
IQVIA presently has a consensus price target of $258.40, indicating a potential upside of 17.87%. ICON Public has a consensus price target of $345.30, indicating a potential upside of 8.15%. Given IQVIA's higher probable upside, research analysts plainly believe IQVIA is more favorable than ICON Public.
IQVIA has higher revenue and earnings than ICON Public. IQVIA is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.
IQVIA has a net margin of 9.01% compared to ICON Public's net margin of 8.30%. IQVIA's return on equity of 29.17% beat ICON Public's return on equity.
IQVIA received 37 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 68.06% of users gave IQVIA an outperform vote while only 65.14% of users gave ICON Public an outperform vote.
Summary
IQVIA beats ICON Public on 11 of the 17 factors compared between the two stocks.
Get IQVIA News Delivered to You Automatically
Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
